23andMe Reveals Promising Data for New Antibody at ASCO
Company Announcements

23andMe Reveals Promising Data for New Antibody at ASCO

The latest announcement is out from 23andMe Holding (ME).

23andMe Holding Co. announced promising preliminary safety and efficacy data for their innovative anti-CD200R1 antibody, 23ME-00610, at the prestigious 2024 ASCO Annual Meeting. This exciting development has not been officially filed for regulatory purposes but offers potential future implications for the company’s stakeholders and the medical community keen on advancements in clinical treatments.

For detailed information about ME stock, go to TipRanks’ Stock Analysis page.

Related Articles
GlobeNewswire23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel
TheFly23andMe, Nightingale Health collaborate to pilot blood biomarker panel
TipRanks Auto-Generated Newsdesk23andMe Offers Jargon-Free Investor Insights Online
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!